The concept Frederic describes of not treating the result of inflammation, rather the cause is next level. We have reason to be optimistic in LAG-3’s role in inflammation with GSK continuing development of IMP731. IMP761 could be an incredibly important medicine for patients, and blockbuster for shareholders. The Immutep pipeline is extraordinary, and will take a kings ransom for a large commercial organization to bring in.
Ann: Progress towards clinical development of IMP761, page-6
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
0.005(1.56%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.5¢ | 31.5¢ | $465.8K | 1.452M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 587491 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 18585 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |
